Tounjian Advisory Partners’s AbbVie ABBV Stock Holding History

Tounjian Advisory Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$165K	Sell	657 -9,999	-94%	-$2.15M	0.07%	134
2026 Q1	$2.32M	Sell	10,656 -354	-3%	-$78.5K	0.84%	33
2025 Q4	$2.52M	Sell	11,010 -1,044	-9%	-$238K	0.85%	31
2025 Q3	$2.79M	Sell	12,054 -3,886	-24%	-$791K	0.93%	27
2025 Q2	$3.34M	Sell	15,940 -350	-2%	-$65K	0.65%	40
2025 Q1	$3.41M	Buy	+16,290	New	+$3.17M	0.64%	42

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tounjian Advisory Partners's ABBV Position: Q2 2026 in Review

Tounjian Advisory Partners reduced its AbbVie (ABBV) stake by 94% in Q2 2026, selling an estimated $2.15M and leaving 657 shares worth $165K. The position accounts for 0.07% of the portfolio, ranked #134.

Tounjian Advisory Partners first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.41M in Q1 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Tounjian Advisory Partners held 657 shares of AbbVie worth $165K as of Q2 2026.
Tounjian Advisory Partners sold 9,999 AbbVie shares in Q2 2026, an estimated $2.15M.
AbbVie made up 0.07% of Tounjian Advisory Partners's portfolio in Q2 2026, its #134 holding.
Tounjian Advisory Partners first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
Tounjian Advisory Partners's AbbVie position peaked at $3.41M in Q1 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.